Anavex Life Sciences Corp. (AVXL) Financials

AVXL Assets vs Liabilities

DateAssetsLiabilities
2023-12-31 148.1 million 12.5 million
2023-09-30 154.4 million 12.5 million
2023-06-30 157.8 million 11.1 million
2023-03-31 159.2 million 14.0 million

AVXL Free Cash Flow and Stock based compensation

Graph available only for supporters. Become a supporter to see it.
DateFree Cash FlowStock based compensation
2023-12-31 -7.3 million 2.3 million
2023-09-30 -5.8 million 3.2 million
2023-06-30 -7.7 million 3.9 million
2023-03-31 -8.5 million 4.0 million

AVXL Net Income

No data available :(

AVXL Cash and Debt

Graph available only for supporters. Become a supporter to see it.
DateCashDebtCapital Lease
2023-12-31 143.8 million - -
2023-09-30 151.0 million - -
2023-06-30 154.8 million - -
2023-03-31 153.5 million - -

AVXL Shares Outstanding

Graph available only for supporters. Become a supporter to see it.
DateShares Outstanding
2023-12-31 82.1 million
2023-09-30 79.8 million
2023-06-30 80.9 million
2023-03-31 78.3 million

AVXL Expenses

Graph available only for supporters. Become a supporter to see it.
DateCapexR&DG&AS&M
2023-12-31 - 8.7 million 2.6 million -
2023-09-30 - 10.1 million 2.6 million -
2023-06-30 - 10.3 million 3.2 million -
2023-03-31 - 11.3 million 2.9 million -

AVXL Cost of Revenue

Graph available only for supporters. Become a supporter to see it.
DateRevenueCost of Revenue
2023-12-31 - -
2023-09-30 - -
2023-06-30 - -
2023-03-31 - -

AVXL

Price: $3.79

52 week price:
3.25
10.45

Earnings Per Share: -0.54 USD

P/E Ratio: -9.09

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Volume: 1.1 million

Ebitda: -4.1 million

Market Capitalization: 316.1 million

Links: